Leber hereditary optic neuropathy in Slovenia: quality of life and costs from patient perspective.

IF 3.4 2区 医学 Q2 GENETICS & HEREDITY
Marko Hawlina, Lea Kovač, Katarína Breciková, Jan Žigmond, Vladimír Rogalewicz, Aleš Tichopád, Martin Višňanský, Ivana Šarkanová
{"title":"Leber hereditary optic neuropathy in Slovenia: quality of life and costs from patient perspective.","authors":"Marko Hawlina, Lea Kovač, Katarína Breciková, Jan Žigmond, Vladimír Rogalewicz, Aleš Tichopád, Martin Višňanský, Ivana Šarkanová","doi":"10.1186/s13023-024-03329-0","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Leber hereditary optic neuropathy (LHON) is the most commonly diagnosed mitochondrial disorder, resulting in colour vision abnormalities and rapid but painless deterioration of central vision. While numerous studies have assessed the impact of LHON on the quality of life (QoL) of LHON patients, the financial impact of the disease remains unexplored. This study attempts to calculate both the direct non-medical costs and the indirect costs associated with productivity losses experienced by people with LHON and their unpaid caregivers in Slovenia, in addition to assessing their QoL. Due to the rarity of the disease, the study involved a small sample size, which is important to note for interpreting the results.</p><p><strong>Methods: </strong>The analysis was conducted on nine adult participants diagnosed with LHON, representing one-third of the total number of known Slovenian patients with this condition. To thoroughly assess the economic and social impact of LHON, tailored questionnaires were designed to collect information on demographics, socioeconomic status, LHON severity, and associated non-medical and indirect costs.</p><p><strong>Results: </strong>The mean age of the study participants was 48.8 years (SD 13.3; n = 9). The annual productivity loss attributable to LHON, taking both absenteeism and relative presenteeism into account, was calculated to be EUR 11,608 per person affected. The mean VFQ-25 score, a measure of vision-related quality of life, for adult LHON patients was 30.4 (SD 12.9).</p><p><strong>Conclusion: </strong>The findings highlight the significant economic and social burden of LHON on patients and their families. Ensuring prompt, accurate diagnosis, access to treatment, financial support, and psychological counselling and services are critical to helping individuals cope with and mitigate the profound challenges of vision loss and living with LHON.</p>","PeriodicalId":19651,"journal":{"name":"Orphanet Journal of Rare Diseases","volume":null,"pages":null},"PeriodicalIF":3.4000,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11365147/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Orphanet Journal of Rare Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13023-024-03329-0","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Leber hereditary optic neuropathy (LHON) is the most commonly diagnosed mitochondrial disorder, resulting in colour vision abnormalities and rapid but painless deterioration of central vision. While numerous studies have assessed the impact of LHON on the quality of life (QoL) of LHON patients, the financial impact of the disease remains unexplored. This study attempts to calculate both the direct non-medical costs and the indirect costs associated with productivity losses experienced by people with LHON and their unpaid caregivers in Slovenia, in addition to assessing their QoL. Due to the rarity of the disease, the study involved a small sample size, which is important to note for interpreting the results.

Methods: The analysis was conducted on nine adult participants diagnosed with LHON, representing one-third of the total number of known Slovenian patients with this condition. To thoroughly assess the economic and social impact of LHON, tailored questionnaires were designed to collect information on demographics, socioeconomic status, LHON severity, and associated non-medical and indirect costs.

Results: The mean age of the study participants was 48.8 years (SD 13.3; n = 9). The annual productivity loss attributable to LHON, taking both absenteeism and relative presenteeism into account, was calculated to be EUR 11,608 per person affected. The mean VFQ-25 score, a measure of vision-related quality of life, for adult LHON patients was 30.4 (SD 12.9).

Conclusion: The findings highlight the significant economic and social burden of LHON on patients and their families. Ensuring prompt, accurate diagnosis, access to treatment, financial support, and psychological counselling and services are critical to helping individuals cope with and mitigate the profound challenges of vision loss and living with LHON.

斯洛文尼亚的 Leber 遗传性视神经病变:从患者角度看生活质量和成本。
简介莱伯遗传性视神经病变(LHON)是最常见的线粒体疾病,会导致色觉异常和快速但无痛的中心视力衰退。虽然已有许多研究评估了 LHON 对 LHON 患者生活质量(QoL)的影响,但该疾病对经济的影响仍未得到探讨。本研究除评估斯洛文尼亚 LHON 患者的生活质量外,还试图计算 LHON 患者及其无偿照顾者的直接非医疗成本和与生产力损失相关的间接成本。由于该疾病的罕见性,研究涉及的样本量较小,这对于解释研究结果非常重要:分析对象为九名确诊患有 LHON 的成年参与者,占斯洛文尼亚已知 LHON 患者总数的三分之一。为了全面评估LHON对经济和社会的影响,我们设计了量身定制的调查问卷,以收集有关人口统计学、社会经济状况、LHON严重程度以及相关非医疗和间接成本的信息:研究参与者的平均年龄为 48.8 岁(SD 13.3;n = 9)。考虑到缺勤率和相对缺勤率,每位患者每年因 LHON 造成的生产力损失为 11,608 欧元。成年 LHON 患者的平均 VFQ-25 分数(衡量与视力相关的生活质量)为 30.4(标准差 12.9):研究结果凸显了LHON对患者及其家庭造成的巨大经济和社会负担。确保及时、准确的诊断、获得治疗、经济支持以及心理咨询和服务,对于帮助患者应对和减轻视力丧失和 LHON 带来的巨大挑战至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Orphanet Journal of Rare Diseases
Orphanet Journal of Rare Diseases 医学-医学:研究与实验
CiteScore
6.30
自引率
8.10%
发文量
418
审稿时长
4-8 weeks
期刊介绍: Orphanet Journal of Rare Diseases is an open access, peer-reviewed journal that encompasses all aspects of rare diseases and orphan drugs. The journal publishes high-quality reviews on specific rare diseases. In addition, the journal may consider articles on clinical trial outcome reports, either positive or negative, and articles on public health issues in the field of rare diseases and orphan drugs. The journal does not accept case reports.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信